Global Hyperhidrosis Treatment Market Research Report 2024
Published on: 2024-01-04 | No of Pages : 400 | Industry : Medical
Publisher : MRA | Format : PDF
Global Hyperhidrosis Treatment Market Research Report 2024
In some people, the body’s mechanism for cooling itself is overactive — so overactive that they may sweat four or five times more than is necessary, or normal. When sweating is this extreme it can be embarrassing, uncomfortable, anxiety-inducing, dangerous, and disabling. It often disrupts all aspects of a person's life, from career choices and recreational activities to relationships, emotional well-being, and self-confidence. This kind of excessive sweating is a serious medical condition. It's called hyperhidrosis and it afflicts millions of people around the world (nearly 5% of the world's population). But, due to lack of awareness among sufferers and lack of education among medical professionals, most people are never diagnosed or relieved of their symptoms.
According to MRAResearch’s new survey, global Hyperhidrosis Treatment market is projected to reach US$ 1921.1 million in 2033, increasing from US$ 1302 million in 2022, with the CAGR of 5.5% during the period of 2023 to 2033. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Hyperhidrosis Treatment market research.
Global top 5 players of hyperhidrosis treatment include Allergan (AbbVie), GlaxoSmithKline, Cynosure, Journey Medical Corporation and miraDry. As the largest player, Allergan (AbbVie) makes up over a quarter.
North America ranks first in terms of market size by region, making up around 35%, followed by Europe and Asia-Pacific.
Based on the product type, the hyperhidrosis treatment is primarily split into medications, surgical treatments and physiotherapy, etc. Among them, medical is the largest segment, with a share over 45%.
Hyperhidrosis treatment is mainly used for primary focal hyperhidrosis and secondary generalized hyperhidrosis, in which the former one dominates with a share over 60%.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2033), aims to help readers to get a comprehensive understanding of global Hyperhidrosis Treatment market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Allergan (AbbVie)
GlaxoSmithKline
Cynosure
Journey Medical Corporation
miraDry
Alma Lasers
Carpe
Duradry
Merz Ultherapy
Fotona
BTXA
Seaford Pharmaceuticals
Robugen GmbH
Segment by Type
Medications
Surgical Treatments
Physiotherapy
Primary Focal Hyperhidrosis
Secondary Generalized Hyperhidrosis
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
The Hyperhidrosis Treatment report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Global market size, regional market size. Market Opportunities and Challenges
Chapter 3Companies’ Competition Patterns
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6 to 10Country Level Value Analysis
Chapter 11Companies' Outline
Chapter 12Market Conclusions
Chapter 13Research Methodology and Data Source
According to MRAResearch’s new survey, global Hyperhidrosis Treatment market is projected to reach US$ 1921.1 million in 2033, increasing from US$ 1302 million in 2022, with the CAGR of 5.5% during the period of 2023 to 2033. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Hyperhidrosis Treatment market research.
Global top 5 players of hyperhidrosis treatment include Allergan (AbbVie), GlaxoSmithKline, Cynosure, Journey Medical Corporation and miraDry. As the largest player, Allergan (AbbVie) makes up over a quarter.
North America ranks first in terms of market size by region, making up around 35%, followed by Europe and Asia-Pacific.
Based on the product type, the hyperhidrosis treatment is primarily split into medications, surgical treatments and physiotherapy, etc. Among them, medical is the largest segment, with a share over 45%.
Hyperhidrosis treatment is mainly used for primary focal hyperhidrosis and secondary generalized hyperhidrosis, in which the former one dominates with a share over 60%.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2033), aims to help readers to get a comprehensive understanding of global Hyperhidrosis Treatment market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
Allergan (AbbVie)
GlaxoSmithKline
Cynosure
Journey Medical Corporation
miraDry
Alma Lasers
Carpe
Duradry
Merz Ultherapy
Fotona
BTXA
Seaford Pharmaceuticals
Robugen GmbH
Segment by Type
Medications
Surgical Treatments
Physiotherapy
Segment by Application
Primary Focal Hyperhidrosis
Secondary Generalized Hyperhidrosis
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
The Hyperhidrosis Treatment report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Global market size, regional market size. Market Opportunities and Challenges
Chapter 3Companies’ Competition Patterns
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6 to 10Country Level Value Analysis
Chapter 11Companies' Outline
Chapter 12Market Conclusions
Chapter 13Research Methodology and Data Source